Cormorant Asset Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Cormorant Asset Management LP
CRD #167820
SEC #801-79513
CIK #0001583977
AUM 3,838.6 M (2026-05-27)
Employees 12 (25% Investors, 0% Brokers)
Fees
Minimum
Phone857-702-0370
Address200 Clarendon Street
Boston, MA 02116
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
6.04.83.62.41.20.02010201520212027
Fees and Compensation — Form ADV Part 2A (5/27/2026) [Brochure]
ITEM 5 – FEES AND COMPENSATION

Management Fees, Performance Allocation, and Carried Interest Distributions

With respect to the Hedge Fund, Cormorant receives a monthly management fee, in advance, in an amount
equal to 0.1667% (2.0% annualized) of each Investor’s Series A capital account and 0.125% (1.5%
annualized) of each Investor’s Series F capital account, generally calculated based on the net asset value of
the applicable Investors’ investment as of the beginning of each month and computed prior to the payment
or accrual of any performance allocation. The General Partner is entitled to receive an annual performance
allocation equal to 20.0% of the net appreciation in the value of each Investor’s Series A capital account
and 17.5% of the net appreciation in the value of each Investor’s Series F capital account, which are both
subject to a customary high-water mark. Series F was available to Investors at the Hedge Fund’s launch
and is currently closed.

With respect to the PE Funds, Cormorant receives a quarterly management fee at the beginning of each
calendar quarter in an amount equal to 0.25% (1.0% annualized) or 0.50% (2.0% annualized) of the sum of
(i) the aggregate net capital contributions of each Investor in the fund attributable to the cost of investments
in Portfolio Companies that have not yet made an initial public offering and (ii) the capital account balance
of such Investor attributable to each Portfolio Company that has made an initial public offering, payable
until the end of each of the Fund's Term, as defined in each of the Funds’ offering and governing documents.
In addition, the General Partner may receive carried interest distributions (the “Carried Interest
Distributions”), based on, among other factors, return of paid-in capital contributions, proceeds received by
the Fund and the preferred return and subject to a clawback provision. The Carried Interest Distributions
are generally deducted from proceeds distributed by the PE Funds from time to time (including upon the
liquidation of the Fund) as determined by its General Partner. Additionally, PE Fund III offered limited
parentship interests with 1% management fee and 30% carried interest that was calculated in the same
manner noted above.

The management fee, performance allocation, and Carried Interest Distributions may, in the sole discretion
of Cormorant or the General Partners (as applicable), be waived, reduced, or rebated for certain Investors,
including affiliates of the General Partners or Cormorant.

Cormorant also receives from the Account an asset-based monthly management fee and an annual
performance-based fee, subject to a customary high-water mark, in the amounts set forth in the agreement
between Cormorant and the Account investor.

Cormorant will reduce the management fee by 100% of (i) the Funds’ share of directors’ fees paid by
Portfolio Companies to Cormorant or its affiliates and their respective managers, members, or employees
directly attributable to the Funds’ investment in such Portfolio Companies and (ii) all net fee income

received by Cormorant, its affiliates, and their members or employees (not otherwise employed by or
engaged as a consultant or other service provider by a Portfolio Company) from Portfolio Companies
directly attributable to the Funds’ investment in such Portfolio Companies.

Investors invested in the Advisory Clients do not have the ability to choose to be billed directly for fees
incurred. Cormorant (or an affiliate) deducts fees from Investor assets invested in the Advisory Clients.
Cormorant shares a portion of the management fees with Cormorant PR in exchange for the advisory
services Cormorant PR provides to the Advisory Clients.

Other Fees and Expenses

In connection with the investment management services it provides, Cormorant will bear all of its own
normal and recurring operating expenses and overhead costs, except that research and research-related
expenses may be paid for through the permitted use of “soft dollars” (as described in Item 12 - Brokerage
Practices). The management fee may exceed the expenses borne by Cormorant on behalf of its Advisory
Clients.

In addition to fees payable to Cormorant, the Advisory Clients, and therefore their respective Investors, may
pay a variety of expenses related to each Advisory Client’s investments and operations, including, without
limitation, brokerage and other transaction costs, clearing and settlement charges, trade break fees,
consulting expenses, research expenses (including research-related travel expenses), legal fees and other
expenses in connection with conducting due diligence and negotiating the terms of certain investments,
custodial fees, initial and variation margin, interest and commitment fees on debit balances or borrowings,
stock borrowing fees and proxy solicitation expenses, legal expenses, audit and tax preparation expenses,
accounting fees, costs of the administration of the Advisory Clients (including, but not limited to, fees and
expenses of an administrator and third party valuation services), regulatory costs and expenses (including
filing and licensing fees), organizational expenses, premiums for liability insurance, fees for risk
management services, indemnification expenses, entity-level taxes, issue or transfer taxes, costs of reporting
to Investors, costs of litigation, any extraordinary expenses, and other similar expenses related to the
Advisory Clients. Certain Advisory Clients, including the PE Funds, will also bear expenses related to the
purchase, sale, recapitalization, or refinancing of Portfolio Companies (including broken deal expenses),
placement agent fees, legal fees, and other expenses in connection with conducting due diligence and
negotiating the terms of investments in Portfolio Companies.
Account Minimums and Types of Clients — Form ADV Part 2A (5/27/2026) [Brochure]
ITEM 7 – TYPES OF CLIENTS

As previously described in Item 4, Cormorant’s clients consist of the Hedge Fund, the PE Funds, and the
Account. Investors in the Hedge Fund and the PE Funds consist of institutional investors and other
sophisticated investors.

The minimum investment for an Investor in the Hedge Fund is $1,000,000, which may be reduced by the
Onshore Feeder’s General Partner or the Offshore Feeder’s Board of Directors, as applicable. The interests
in the Onshore Feeder may only be purchased by investors that are “accredited investors,” as defined in
Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), and “qualified
purchasers,” as defined in Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended. U.S.
investors in the Offshore Feeder must also be “accredited investors” and “qualified purchasers.” Shares in
the Offshore Feeder are typically offered to eligible investors that are not U.S. persons or U.S. tax-exempt
entities.

The minimum capital commitment for an Investor in the PE Funds is $5,000,000. The General Partner, in
its discretion, reserves the right to reject or accept only a portion of the capital commitment of any
prospective Investor. Capital commitments of lesser amounts may be accepted at the General Partner’s
discretion. The interests are being offered only to investors that are “accredited investors” and “qualified
purchasers.” The General Partner may admit certain friends and family as Investors on terms that are more
preferential than those that are generally available to Investors.

The Account was established for a sophisticated institutional investor and involves a significant minimum
investment.
Sector Form 13F Holdings Value ($B)
Praxis Precision Medicines Inc 0.3
Helix Acquisition Corp II 0.2
Psivida Corp 0.1
Edgewise Therapeutics Inc 0.1
Erasca Inc 0.1
Rapport Therapeutics Inc 0.1
Alumis Inc 0.1
Abivax Sa 0.1
Helix Acquisition Corp 0.1
Magenta Therapeutics Inc 0.1
View All
Holdings by Sector ($B)
5.04.03.02.01.00.02013201720222027
Type Form D Funds Date Sold AUM
PE Cormorant Private Healthcare Fund VI LP [2026-02-11] 75.2 M 102.9 M
Offered $400,000,000 · Filed 2025-11-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining $324,800,000 · Duration More than one year · Revenue Decline to Disclose
PE Cormorant Private Healthcare Fund V LP [2023-11-13] 318.0 M 491.7 M
Offered $318,000,000 · Filed 2024-08-08 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $5,000,000 · Duration One year or less · Revenue Decline to Disclose
PE Cormorant Private Healthcare Fund IV LP [2021-11-15] 252.7 M 426.3 M
Offered $400,000,000 · Filed 2021-08-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $147,314,000 · Duration One year or less · Revenue Decline to Disclose
PE Cormorant Private Healthcare Fund III LP [2020-11-27] 206.3 M 429.5 M
Offered $419,913,000 · Filed 2021-06-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $213,650,000 · Duration One year or less · Revenue Decline to Disclose
PE Cormorant Private Healthcare Fund II LP [2018-11-26] 105.5 M 125.2 M
Offered $350,000,000 · Filed 2018-08-17 (D) · Exemption 506(b), 3(c)(7) · Remaining $244,450,000 · Duration One year or less · Revenue Decline to Disclose
PE Cormorant Private Healthcare Fund I LP [2016-03-30] 29.0 M 49.8 M
Offered $250,000,000 · Filed 2016-01-15 (D) · Exemption 506(b), 3(c)(7) · Minimum $5,000,000 · Remaining $221,040,010 · Duration One year or less · Revenue Decline to Disclose
HF Cormorant Global Healthcare Master Fund LP [2013-06-14] 589.2 M 2,204.4 M
Filed 2026-03-03 (D/A) · Exemption 506(b) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 15 3.8
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 1 0.0
Total 16 3.8
By Discretionary
Discretionary 16 3.8
Non-Discretionary 0 0.0
Total 16 3.8
By Non-United States Persons
Non-United States Persons 0.8
United States Persons 3.1
Total 16 3.8
Form D Directors Role # Filings # Firms 2011 - 2026
Kevin Phillip Director 193 39
Paras Malde Director 77 26
Dms Fund Governance I Ltd Director 10 4
Jay Scollins Executive Officer 17 3
Dms Fund Governance II Ltd Director 6 3
Bihua Chen Executive Officer 48 2
Cormorant Asset Management LP Executive Officer, Promoter 12 2
Caleb Tripp Executive Officer 8 2
Cormorant Asset Management LLC Executive Officer, Promoter 4 2
Cormorant Private Healthcare GP II LLC Executive Officer 2 2
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001583977]
3 [0001583977]
4 [0001583977]
SC 13D [0001583977]
SC 13G [0001583977]
Form 13D/13G Filer Form 13D/13G Subject Filed
Cormorant Asset Management LP Agomab Therapeutics NV [2026-05-15]
Cormorant Asset Management LP Adlai Nortye Ltd [2026-05-15]
Cormorant Asset Management LP Rallybio Corp [2026-05-15]
Cormorant Asset Management LP Engene Holdings Inc [2026-02-17]
Cormorant Asset Management LP Moonlake Immunotherapeutics [2026-02-17]
Cormorant Asset Management LP IBIO Inc [2025-11-14]
Cormorant Asset Management LP Cabaletta Bio Inc [2025-08-14]
Cormorant Asset Management LP Cargo Therapeutics Inc [2025-05-15]
Cormorant Asset Management LP Bioage Labs Inc [2025-02-14]
Cormorant Asset Management LP Kala Bio Inc [2025-02-14]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
Form 3/4/5 Subject 2011 - 2026
Cormorant Global Healthcare Master Fund LP
Cormorant Asset Management LP
Chen Bihua
Bright Minds Biosciences Inc
SAV Acquisition Corp
EyePoint Inc
MoonLake Immunotherapeutics
Cormorant Private Healthcare Fund II LP
Cormorant Private Healthcare Fund III LP
Cormorant Private Healthcare Fund IV LP
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
SAV Acquisition Corp CRBP
Common Stock
2025-12-11 Sell 30,029 $11.46 344,132
EyePoint Inc EYPT
Common Stock
2025-12-04 Sell 60,000 $15.70 942,000
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
2025-09-30 Sell 5,827 $6.96 40,556
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
2025-09-29 Sell 2,800,000 $6.61 18,508,000
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
2025-09-29 Sell 3,390,943 $7.58 25,703,348
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
2025-09-29 Sell 232,460 $8.40 1,952,664
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
2025-09-29 Sell 70,748 $9.38 663,616
Biomea Fusion Inc BMEA
Stock Option (Right to Buy) · derivative
2025-06-11 Grant 91,970 $0.00
OnKure Therapeutics Inc OKUR
Class A Common Stock
2025-05-15 Sell 1,813,439 $1.85 3,354,862
OnKure Therapeutics Inc OKUR
Class A Common Stock
2025-05-12 Sell 24,300 $1.99 48,357
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
2025-02-14 Conversion 6,780,810
Aardvark Therapeutics Inc AARD
Common Stock
2025-02-14 Buy 187,500 $16.00 3,000,000
Aardvark Therapeutics Inc AARD
Common Stock
2025-02-14 Conversion 800,189
Bright Minds Biosciences Inc DRUG
Common Shares
2024-11-04 Buy 184,331 $21.70 3,999,983
Bright Minds Biosciences Inc DRUG
Common Shares
2024-10-16 Buy 7,150 $24.03 171,814
Bright Minds Biosciences Inc DRUG
Common Shares
2024-10-16 Buy 39,743 $23.22 922,832
Bright Minds Biosciences Inc DRUG
Common Shares
2024-10-16 Buy 3,107 $25.22 78,359
Bright Minds Biosciences Inc DRUG
Common Shares
2024-10-15 Buy 63,173 $5.92 373,984
Bright Minds Biosciences Inc DRUG
Common Shares
2024-10-15 Buy 33,343 $6.42 214,062
Bright Minds Biosciences Inc DRUG
Common Shares
2024-10-15 Buy 8,900 $7.31 65,059
showing 20 of 200 most recent transactions
Comparable Firms State AUM
Hudson Structured Capital Management Ltd
CT 4,028.4 M
Glade Brook Capital Partners LLC
CT 3,955.0 M
Avenue Europe International Management LP
NY 3,912.4 M
Cyrus Capital Partners LP
NY 3,866.5 M
Tree Line Capital Partners LLC
CA 3,847.7 M
Vector Capital Management LP
CA 3,751.0 M
Anchorage Capital Group LLC
NY 3,707.6 M
Resource Capital Investment Corporation
CA 3,706.7 M
Boussard & Gavaudan Investment Management LLP
3,679.1 M
Soleus Capital Management LP
CT 3,663.3 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com